Clinical features and quality of life in patients with different phenotypes of Crohn's disease of the ileal pouch
- PMID: 17665259
- DOI: 10.1007/s10350-007-0284-8
Clinical features and quality of life in patients with different phenotypes of Crohn's disease of the ileal pouch
Abstract
Purpose: Crohn's disease of the pouch can occur in patients with colectomy and ileal pouch-anal anastomosis performed for ulcerative colitis. The clinical features of inflammatory, fibrostenotic, and fistulizing Crohn's disease have not been characterized.
Methods: A total of 73 eligible patients with Crohn's disease of the pouch, who were seen in the Pouchitis Clinic, were enrolled: 25 with inflammatory Crohn's disease, 17 with fibrostenotic Crohn's disease, and 31 with fistulizing Crohn's disease. The clinical phenotypes of Crohn's disease were based on a combined assessment of clinical, endoscopic, radiographic, and histologic features. Clinical symptoms, endoscopic and histologic features, and health-related quality-of-life scores were assessed.
Results: Demographic and clinical features, including preoperative and postoperative parameters, were similar between the three phenotypes of Crohn's disease of the pouch. The use of nonsteroidal anti-inflammatory drugs, neuropsychiatric drugs, antidiarrheal agents, and Crohn's disease medicines was not different between the three groups. Predominant symptoms, as expected, were significantly different between the three phenotypes: diarrhea and/or pain in 92 percent of patients with inflammatory Crohn's disease, obstructive symptoms in 64.7 percent of patients with fibrostenotic Crohn's disease, and fistular drainage in 51.6 percent of those with fistulizing Crohn's disease (P < 0.0001). There was no statistical difference in quality-of-life scores between the three phenotypes, adjusted for disease activity. There was no significant correlation between quality-of-life and symptom scores in any of the three groups. Although not statistically significant, patients with fistulizing Crohn's disease (16.1 percent) tended to have an increased risk for pouch failure compared with inflammatory (8 percent) or fibrostenotic (5.9 percent) Crohn's disease.
Conclusions: Predominant symptoms were different in clinical phenotypes of Crohn's disease. Each of the three phenotypes of Crohn's disease similarly affected quality-of-life. Fistulizing Crohn's disease may be associated with a higher risk for pouch failure.
Similar articles
-
Risk factors for clinical phenotypes of Crohn's disease of the ileal pouch.Am J Gastroenterol. 2006 Dec;101(12):2760-8. doi: 10.1111/j.1572-0241.2006.00838.x. Am J Gastroenterol. 2006. PMID: 17227523
-
Crohn's disease and indeterminate colitis and the ileal pouch-anal anastomosis: outcomes and patterns of failure.Dis Colon Rectum. 2005 Aug;48(8):1542-9. doi: 10.1007/s10350-005-0059-z. Dis Colon Rectum. 2005. PMID: 15937625
-
Serologic responses in indeterminate colitis patients before ileal pouch-anal anastomosis may determine those at risk for continuous pouch inflammation.Dis Colon Rectum. 2005 Jun;48(6):1254-62. doi: 10.1007/s10350-005-0013-0. Dis Colon Rectum. 2005. PMID: 15868228
-
[Ileal pouch-anal anastomosis for Crohn's disease. Current status].Cir Esp. 2009 Feb;85(2):69-75. doi: 10.1016/j.ciresp.2008.09.005. Epub 2009 Feb 5. Cir Esp. 2009. PMID: 19231461 Review. Spanish.
-
Clinical approach to diseases of ileal pouch-anal anastomosis.Am J Gastroenterol. 2005 Dec;100(12):2796-807. doi: 10.1111/j.1572-0241.2005.00278.x. Am J Gastroenterol. 2005. PMID: 16393238 Review.
Cited by
-
Diagnosis and differential diagnosis of Crohn's disease of the ileal pouch.Curr Gastroenterol Rep. 2012 Oct;14(5):406-13. doi: 10.1007/s11894-012-0282-4. Curr Gastroenterol Rep. 2012. PMID: 22855236 Review.
-
Is pyloric gland metaplasia in ileal pouch biopsies a marker for Crohn's disease?Dig Dis Sci. 2013 Oct;58(10):2918-25. doi: 10.1007/s10620-013-2655-4. Epub 2013 Mar 30. Dig Dis Sci. 2013. PMID: 23543088
-
Inflammatory Pouch Conditions Are Common After Ileal Pouch Anal Anastomosis in Ulcerative Colitis Patients.Inflamm Bowel Dis. 2020 Jun 18;26(7):1079-1086. doi: 10.1093/ibd/izz227. Inflamm Bowel Dis. 2020. PMID: 31587035 Free PMC article.
-
α4β7 Integrin Antagonist Vedolizumab for the Treatment of Refractory Ileitis.Case Rep Gastrointest Med. 2019 Apr 22;2019:2091089. doi: 10.1155/2019/2091089. eCollection 2019. Case Rep Gastrointest Med. 2019. PMID: 31143480 Free PMC article.
-
Pouchitis: Clinical Features, Diagnosis, and Treatment.Int J Gen Med. 2021 Jul 24;14:3871-3879. doi: 10.2147/IJGM.S306039. eCollection 2021. Int J Gen Med. 2021. PMID: 34335051 Free PMC article. Review.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical